AXONICS INC (AXNX)
US05465P1012 - Common Stock
Taking everything into account, AXNX scores 5 out of 10 in our fundamental rating. AXNX was compared to 192 industry peers in the Health Care Equipment & Supplies industry. AXNX has a great financial health rating, but its profitability evaluates not so good. AXNX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
AXNX had positive earnings in the past year.
In the past year AXNX has reported a negative cash flow from operations.
AXNX had negative earnings in each of the past 5 years.
AXNX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
AXNX has a Return On Assets of -0.85%. This is in the better half of the industry: AXNX outperforms 69.23% of its industry peers.
AXNX's Return On Equity of -0.95% is fine compared to the rest of the industry. AXNX outperforms 70.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -0.95% | ||
| ROIC | N/A |
ROA(3y)-8.17%
ROA(5y)-15.38%
ROE(3y)-9.34%
ROE(5y)-18.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 74.94%, AXNX belongs to the best of the industry, outperforming 85.64% of the companies in the same industry.
In the last couple of years the Gross Margin of AXNX has grown nicely.
The Profit Margin and Operating Margin are not available for AXNX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.58%
GM growth 5Y5.57%
2. Health
2.1 Basic Checks
AXNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AXNX has more shares outstanding
There is no outstanding debt for AXNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AXNX has an Altman-Z score of 25.27. This indicates that AXNX is financially healthy and has little risk of bankruptcy at the moment.
AXNX's Altman-Z score of 25.27 is amongst the best of the industry. AXNX outperforms 96.92% of its industry peers.
There is no outstanding debt for AXNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 25.27 |
ROIC/WACCN/A
WACC10.08%
2.3 Liquidity
AXNX has a Current Ratio of 10.73. This indicates that AXNX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.73, AXNX belongs to the best of the industry, outperforming 92.82% of the companies in the same industry.
A Quick Ratio of 8.98 indicates that AXNX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.98, AXNX belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.73 | ||
| Quick Ratio | 8.98 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 113.85% over the past year.
The Revenue has grown by 33.86% in the past year. This is a very strong growth!
The Revenue has been growing by 249.76% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)113.85%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q1200%
Revenue 1Y (TTM)33.86%
Revenue growth 3Y48.67%
Revenue growth 5Y249.76%
Revenue growth Q2Q27.72%
3.2 Future
The Earnings Per Share is expected to grow by 77.39% on average over the next years. This is a very strong growth
Based on estimates for the next years, AXNX will show a quite strong growth in Revenue. The Revenue will grow by 19.04% on average per year.
EPS Next Y108.25%
EPS Next 2Y110.57%
EPS Next 3Y102.25%
EPS Next 5Y77.39%
Revenue Next Year23.07%
Revenue Next 2Y21.62%
Revenue Next 3Y19.96%
Revenue Next 5Y19.04%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 370.50, which means the current valuation is very expensive for AXNX.
Based on the Price/Earnings ratio, AXNX is valued a bit cheaper than 66.67% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 24.84. AXNX is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 177.91, which means the current valuation is very expensive for AXNX.
Based on the Price/Forward Earnings ratio, AXNX is valued a bit cheaper than 69.23% of the companies in the same industry.
AXNX is valuated expensively when we compare the Price/Forward Earnings ratio to 21.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 370.5 | ||
| Fwd PE | 177.91 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AXNX is valued a bit cheaper than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 362.29 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AXNX does not grow enough to justify the current Price/Earnings ratio.
AXNX's earnings are expected to grow with 102.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.42
PEG (5Y)N/A
EPS Next 2Y110.57%
EPS Next 3Y102.25%
5. Dividend
5.1 Amount
AXNX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AXONICS INC
NASDAQ:AXNX (4/26/2024, 7:00:00 PM)
After market: 66.69 0 (0%)66.69
+0.15 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.40B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 370.5 | ||
| Fwd PE | 177.91 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)3.42
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -0.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.73 | ||
| Quick Ratio | 8.98 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)113.85%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y108.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)33.86%
Revenue growth 3Y48.67%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y